Posted by Michael Wonder on 20 Jun 2019
Novel approaches to value assessment within the cost-effectiveness framework
20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions based on the cost-per-quality-adjusted life-year metric by incorporating into health technology assessment additional elements that create value for patients and society.
Louis Garrison began the session by providing an overview of the recommendations of the International Society for Pharmacoeconomics and Outcomes Research’s Special Task Force on value frameworks.
Jeroen Jansen presented his thoughts on how value assessment might move beyond conventional CEA, introducing the need to acknowledge patient diversity.
Nancy Devlin discussed approaches that may be taken to extend the scope of patient-reported outcomes and quality of life.
